Sugi Predict

Sugi Predict / Compounds / SCHEMBL1663398

SCHEMBL1663398

SCHEMBL1663398

CC(C)c1nc2cc(O)ccc2c(=O)n1-c1ccc(Cl)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPV1 Q8NER1 1/20 0.72
▸ ESR1 P03372 4/20 0.60
▸ ESR2 Q92731 4/20 0.60
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ MIF P14174 1/20 0.44
▸ KDM4E B2RXH2 2/20 0.43
▸ HTR6 P50406 1/20 0.42
▸ KCNH2 Q12809 1/20 0.41
▸ HRH3 Q9Y5N1 1/20 0.41
▸ PDE10A Q9Y233 2/20 0.41
▸ KMT2A Q03164 2/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ TSHR P16473 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1665830 0.91 TRPV1 (0.61) TRPV1ESR1ESR2SMN1; SMN2MIF
SCHEMBL1666292 0.90 TRPV1 (0.60) TRPV1ESR1ESR2SMN1; SMN2MIF
SCHEMBL1664439 0.88 TRPV1 (0.74) TRPV1ESR1ESR2SMN1; SMN2KCNH2
SCHEMBL10445951 0.88 TRPV1 (0.57) TRPV1ESR1ESR2SMN1; SMN2MIF
SCHEMBL10446402 0.88 TRPV1 (0.57) TRPV1ESR1ESR2SMN1; SMN2MIF
SCHEMBL10446158 0.87 TRPV1 (0.72) TRPV1ESR1ESR2KDM4EKCNH2
SCHEMBL1664011 0.87 TRPV1 (0.72) TRPV1ESR1ESR2SMN1; SMN2KCNH2
SCHEMBL1663746 0.86 TRPV1 (0.65) TRPV1ESR1ESR2KCNH2HRH3
SCHEMBL1663858 0.86 TRPV1 (0.55) TRPV1ESR1ESR2SMN1; SMN2KDM4E
SCHEMBL1663040 0.86 ESR1 (0.55) TRPV1ESR1ESR2SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8809528-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2014-08-19 — — US claimed
EP-1755606-B2 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2011-06-29 — — EP claimed
US-9102653-B2 Substituted quinazolinones as vanilloid antagonists NOVARTIS AG (CH) 2015-08-11 — — US disclosed
CN-1956721-B Quinazolinone derivatives as vanilloid antagonists NOVARTIS AG 2015-05-13 — — CN disclosed
US-20140315932-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2014-10-23 — — US disclosed
US-8809528-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2014-08-19 — — US disclosed
US-20130060029-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS CHEN WEICHUN (US) 2013-03-07 — — US disclosed
US-8349852-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2013-01-08 — — US disclosed
US-20120184571-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG 2012-07-19 — — US disclosed
US-8211902-B2 Quinazolinone derivatives useful as vanilloid antagonists NOVARTIS AG (CH) 2012-07-03 — — US disclosed
EP-2387440-A2 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS Novartis AG (CH) 2011-11-23 — — EP disclosed
CN-101356160-A Trisubstituted quinazolinone derivatives as vanilloid antagonists JANSSEN PHARMACEUTICA NV (CH) 2009-01-28 — — CN disclosed
EP-1963283-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS Novartis AG (CH) 2008-09-03 — — EP disclosed
US-20080194595-A1 Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders CITIBANK, N.A., AS NOTES COLLATERAL AGENT 2008-08-14 — — US disclosed
EP-1755606-B1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-10-31 — — EP disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 — — WO disclosed
WO-2007065662-A2 TRISUBSTITUTED QUINAZOLINONE DERIVATIVES AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2007-06-14 — — WO disclosed
CN-1956721-A Quinazolinone derivatives as vanilloid antagonists NOVARTIS AG (CH) 2007-05-02 — — CN disclosed
EP-1755606-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS Novartis AG (CH) 2007-02-28 — — EP disclosed
WO-2005120510-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS NOVARTIS AG (CH) 2005-12-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194595-A1 Bone disorders; osteoporosis; analgesics; muscular disorders; inflammatory bowel disorders CACNA1A, ALPI, CACNA1E TRPV1 57/4885ESR1 2832/4885ESR2 2694/4885
US-20140315932-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS TRPV1, TRPV3, CACNA1A TRPV1 1/4885ESR1 2643/4885ESR2 3042/4885
US-20120184571-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS TRPV1, TRPV3, TRPV5 TRPV1 1/4885ESR1 2881/4885ESR2 3386/4885
US-20130060029-A1 QUINAZOLINONE DERIVATIVES USEFUL AS VANILLOID ANTAGONISTS TRPV1, KCNJ2, TRPV3 TRPV1 1/4885ESR1 3801/4885ESR2 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.